复发转移性头颈部鳞癌的免疫治疗进展

Update in Immunotherapy for Recurrent and Metastatic Squamous Cell Carcinoma of Head and Neck

头颈部鳞癌(squamous cell carcinoma of head andneck,SCCHN)是常见的恶性肿瘤之一。复发转移性SCCHN患者可选的治疗方式和疗效有限,而肿瘤免疫治疗为这些患者提供了新的治疗选择和改善预后的希望。目前国际上已有两种程序性细胞死亡受体-1抑制剂(纳武利尤单抗和帕博利珠单抗)获批用于复发转移性SCCHN患者的二线治疗,获批药物的Ⅲ期临床试验和其他作用于相同途径药物的Ⅱ期临床试验显示,这类药物有助于改善复发转移性SCCHN患者的生存预后,带来持久应答,同时具有较好的安全性,正逐渐成为铂类治疗失败患者治疗的金标准。

Squamous cell carcinoma of head and neck (SCCHN) is one of the common malignant tumors. Patients with recurrent or metastatic SCCHN have limited treatment options with limited efficacy. Tumor immunotherapy offers a new treatment option and hope for improved outcomes. Two programmed cell death-1 ( PD-1 ) inhibitors, nivolumab and pembrolizumab, have been approved for second-line treatment in patients with recurrent and metastatic SCCHN. Phase 2 and 3 clinical trials of the PD-1 pathway inhibitors demonstrated that the immune checkpoint inhibitors could improve survival outcome, with a sustained response and acceptable safety profile, and are gradually becoming one of the standards of care in patients with SCCHN who failed in platinum-based chemotherapy.